Drugs / CiPS-BAL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07312864 | Dec 2025 → Dec 2027 expected | liver failure | Beijing Friendship Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CiPS-BAL | “The goal of this clinical trial is to evaluate the safety and tolerability of a novel bioartificial liver (CiPS-BAL) in patients with liver failure or small-for-size syndrome.” NCT07312864 ↗ |
| Modality | Cell therapy | “Researchers will treat participants with the CiPS-BAL system, which uses hepatocytes derived from chemically induced pluripotent stem cells (CiPS) within a bioartificial liver device.” NCT07312864 ↗ |
| Route | Other | “Therapy is administered via central venous access” NCT07312864 ↗ |